Bruker acquires Optimal companies for pharma software, technologies
Bruker has acquired biopharma solutions provider Optimal Industrial Automation and Technologies. The company said that the acquisition will strengthen it as a key software and solutions provider for small molecule, biologics, and new drug modalities pharma companies. Read More
PathAI, GSK partner to accelerate research, drug development
PathAI and GlaxoSmithKline (GSK) have announced a strategic multiyear partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis. Read More
AACR announces 2022 cancer research award recipients
The American Association for Cancer Research (AACR) and partners Pelotonia and Victoria's Secret have announced five recipients of the Victoria's Secret Global Fund for Women's Cancers 2022 Meritorious Award. Read More
Cha Medical begins construction of $250M Cell Gene Biobank facility
Cha Medical & Bio Group has begun construction of its Cell Gene Biobank facility in Pangyo, South Korea. The facility will be a 710,000 sq ft manufacturing site for cell and gene therapies, as well as a site for stem cell biobanking. The $250 million project is expected to be completed by the end of 2024, the company said. Read More
FDA lifts clinical hold on Immunome's SARS-CoV-2 antibody cocktail
Biopharmaceutical company Immunome said that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its antibody cocktail for the treatment of SARS-CoV-2. Read More
AACR recognizes Salk scientist with lifetime achievement award
Salk Institute Professor Tony Hunter will be awarded the 2022 American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research for his work that led to the development of the leukemia drug imatinib (Gleevec). Read More
CellOrigin closes a new round of investment funding
CellOrigin, a biotech company focusing on immune cell therapies derived from induced pluripotent stem cells, has secured a new round of approximately 100 million renminbi (approximately $16 million U.S.) of investment funding. Read More
Anixa Biosciences initiates new CAR-T clinical trial
Anixa Biosciences initiated a phase I trial evaluating its CAR-T cell therapy at the Moffitt Cancer Center. Read More
Regenerative medicine: Disrupting the status quo in 2021
Regenerative medicine is taking aim at cancer and a wide range of other prevalent and rare diseases, according to the 2021 annual report of the Alliance for Regenerative Medicine. Read More
Vita Therapeutics bolsters leadership
Cell engineering firm Vita Therapeutics has added three new senior vice presidents to its executive lineup. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
